
|Videos|June 22, 2017
Impact of MET Inhibitors in MET Exon 14-Mutant NSCLC
Author(s)Mark Awad, MD, PhD
Mark Awad, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses the impact of MET inhibitors on survival among patients with <em>MET</em> exon 14-mutant non–small cell lung cancer.
Advertisement
Mark Awad, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses the impact of MET inhibitors on survival among patients withMET
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















